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Calpainis a common neurological disorder associated with HIV-1 infection and AIDS.
The activity of the HIV trans-activating protein Tat is thought to contribute to neuronal pathogenesis. While
Tat proteins from primary virus isolates consist of 101 or more amino acids, 72 and 86 amino acids forms of
Tat are commonly used for in vitro studies. Although Tat72 contains the minimal domain required for viral
replication, other activities of Tat appear to vary according to its length, sub-cellular localization, cell type and
the stage of cellular differentiation. In this study, we investigated the stability of intracellular Tat101 during
proliferation and differentiation of neuronal cells in culture. We have utilized rat neuronal progenitors as a
model of neuronal cell proliferation and differentiation, as well as rat primary cortical neurons as a model of
fully differentiated cells. Our results indicate that, upon internalization, Tat101 was degraded more rapidly in
proliferating cells than in cells which either underwent neuronal differentiation or were fully differentiated.
Intracellular degradation of Tat was prevented by the calpain 1 inhibitor, ALLN, in both proliferating and
differentiated cells. Inhibition of calpain 1 by calpastatin peptide also prevented Tat cleavage. In vitro calpain
digestion and mass spectrometry analysis further demonstrated that the sequence of Tat sensitive to calpain
cleavage was located in the C-terminus of this viral protein, between amino acids 68 and 69. Moreover,
cleavage of Tat101 by calpain 1 increased neurotoxic effect of this viral protein and presence of the calpain
inhibitor protected neuronal cells from Tat-mediated toxicity.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe HIV-1 transactivating factor Tat, which is secreted by HIV-
infected cells, exerts toxic and non-toxic effects on uninfected
bystander cells, including neurons. Tat protein is encoded by two
exons in the viral genome, one encoding the ﬁrst 72 amino acids and
the other amino acid 73 to 101 or more, up to 113 amino acids [1].
While the full-length, two-exon Tat101, is the most abundant form
isolated from clinical samples, the truncated variants of 72 and 86
amino acids are often utilized for in vitro studies [1,2]. The ﬁrst exon of
Tat (72 aa) is the best characterized with respect to the transactivating
properties of this viral protein, being required for viral replication
[1,3]. The second coding exon of Tat is rather involved in potentiating
the protein activity, at least in monocyte-derived macrophages [4].
Another study has reported that the second exon of Simian
Immunodeﬁciency Virus (SIV) Tat contains a function important for
in vivo replication of SIV in macaques, and that the response of
cytotoxic T lymphocytes (CTL) against this region of Tat inhibits SIV
replication [5]. The functional importance of the last 14 amino acids of
Tat100 has been investigated in T cells, in which full-length Tat had a
reduced ability to induce apoptosis via the extrinsic pathway1 215 204 0679.
l rights reserved.compared to Tat86 [6]. Both Tat 72 and Tat 86 have been shown to
induce neuronal cell death [7–11] and to produce a rapid rise in
intracellular calcium in organotypic slice cultures of rat hippocampus
by a mechanism that required the function of an NMDA receptor
polyamine-sensitive site [12]. Although studies showing neuronal
toxicity of Tat72 or Tat86 may reasonably apply to the full-length
Tat101, no studies have addressed the neurotoxicity of Tat101.
Similarly, studies about secondary modiﬁcations of Tat upon its
cellular uptake are limited to the truncated 72 or 86 amino acid Tat
proteins [13,14]. It is also known that, upon cellular uptake, Tat72 and
Tat86 proteins localize to the nuclear compartment of HeLa HL3T1
cells where they can transactivate the HIV-1 LTR [15]. However,
differently from proliferating cells, we have observed a predominant
cytoplasmic localization of Tat in primary rat cortical neurons and in
brain tissues from HIVE patients [16]. In the same study, we have also
found that, at least in cultured neurons, retention of Tat in the
cytoplasm was mediated by the tubulin-binding domain of Tat. By
transfecting primary neurons with YFP-Tat101, YFP-Tat86, and YFP-
Tat72 expression plasmids, we have further determined that the
afﬁnity of these fusion proteins to the nucleus varied with the length
of Tat, with Tat72 having a stronger nuclear localization than Tat86 or
Tat101 (unpublished observations). Altogether, the above information
indicates that the second exon of Tat could be critical for the
subcellular localization of this protein and, ultimately, for its function.
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Tat86 cleavage by furin endopeptidase in monocytoid cells [14], and
another study demonstrated cleavage of Tat72 by matrix-metallopro-
teinase 1 (MMP-1) in neuronal–glial mixed cultures [17].
Here, we have utilized a rat neuronal progenitor cell line (HCN) as a
model for proliferating cells and cells undergoing neuronal differ-
entiation, as well as primary rat embryonic cortical neurons as a
model of fully differentiated neurons. We found that, soon upon entry
into the cells, Tat protein underwent rapid degradation, which was
delayed in mature neurons or in cells undergoing neuronal differ-
entiation and was prevented, in all instances, by the calpain-1
inhibitor ALLN. Cleavage of intracellular Tat by calpain was also
prevented by pre-treatment of the cells with calpastatin, the
endogenous inhibitor of calpain proteases. In vitro proteolytic cleavage
experiments using various deletion mutants of Tat followed by
electrospray mass spectrometry analysis of the digested peptides
further indicated the presence of a calpain-sensitive site in the
C-terminus of Tat between serine 68 and leucine 69. Functionally,
expression of Tat101 in neuronal progenitors induced the highest
degree of cell death in proliferating cells compared to cells undergoingFig. 1. Stability of Tat in neuronal progenitors. (A)Western blot analysis to detect Tat in HCN n
or differentiating (D) medium for 10 and 24 h. Note that Tat is detectable only in cells undergo
experiment to detect Tat in proliferating and differentiating neuronal progenitors. HCN cells w
to 400 nM recTat101. The band of about 12 kDa is associated to the Tat preparation as explain
shows higher stability of Tat in differentiating than proliferating cells. ⁎ indicates statistically
points (p≤0.05). ⁎⁎ is statistically different from values at 4, 10, and 24 h (p≤0.05).neuronal differentiation, while treatment of cells with the calpain
inhibitor ALLN signiﬁcantly enhanced their survival.
2. Results
The effects of Tat on cell function can depend on its subcellular
localization, protein concentration and cell type [1,18]. In addition, the
stability of Tat and its intracellular processing may also contribute to
Tat-mediated effects. We have utilized HCN neuronal progenitor cells
that can proliferate in vitro or, upon removal of growth factors,
differentiate into neuronal cells. HCN cells were treated with
recombinant Tat101 (recTat101) at a concentration of 5 μg/ml (about
400 nM) in the absence or presence of differentiating medium for 10
and 24 h. After 10 h treatment, Tat was no longer detectable in
proliferating cells, while it was still present in cells undergoing
neuronal differentiation, up to 24 h (Fig. 1A). In a time course
experiment, we evaluated the stability of Tat in proliferating HCN
neuronal progenitors and in cells undergoing neuronal differentiation
(Fig. 1B). According to our data, uptake of the recTat101 was more
efﬁcient in proliferating cells than in cells undergoing neuronaleuronal progenitors after exposure to 400 nM of recombinant Tat 101 in proliferating (P)
ing neuronal differentiation. Anti-Grb2was used for the loading control. (B) Time course
ere cultured in proliferating (P) or differentiating (D) medium for 24 h prior to exposure
ed in the Results section. (C) Densitometric analysis of three independent Western blots
different values fromvalues related to same culturing conditions at all the indicated time
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at 30 min after treatment when compared to differentiating cells at
the same time point (Fig. 1B). Interestingly, the amount of Tat lost in
the ﬁrst 2 h after treatment was greater in proliferating than in
differentiating cells, as also depicted in the diagramwhere the amount
of Tat protein detected in each protein lysate was normalized for the
amount of Grb2 present in the same sample (Fig. 1C). Quantitatively,
about 60% of Tat was lost by proliferating cells in the ﬁrst 2 h after
treatment, and another 30% in the next 2 h (4 h time point). In
contrast, although differentiating cells did uptake Tat less efﬁciently,
they retained at least 40% of Tat up to 10 h. Note that in Fig.1 and in the
following two other ﬁgures the antibody to Tat101 recognizes also a
band of about 12 kDa, which seems speciﬁc to Tat preparation and is
likely a product of Tat degradation. However, it was excluded from
further investigation essentially for two reasons: it is often present at
time zero independently from any treatment and is not necessarily
modulated over time or upon cell treatments (Figs. 1–3).
3. Mechanisms of intracellular degradation of Tat
Since HIV-1 Tat has been shown to activate intracellular calcium,
we next investigated whether calcium-dependent activation of
calpain would affect the stability of intracellular Tat. We pre-treated
HCN cells with the calpain inhibitor ALLN (10 μM) prior to further
treatment with recTat101 in the absence or presence of differentiating
medium. Fig. 2A shows a representative experiment in which Tat
protein (400 nM) was no longer detectable in both proliferating and
differentiating cells after 24 h. However, Tat protein was still
detectable in the presence of the calpain inhibitor, ALLN, in both
proliferating and differentiating cells at 24 and 48 h post-treatment.
Quantiﬁcation and normalization of the bands relative to recTat101
protein from three different experiments again revealed that ALLN
was more effective in HCN cells undergoing neuronal differentiation
when compared to proliferating cells (Fig. 2B).Fig. 2. The calpain inhibitor ALLN prevents Tat degradation in HCN cells. (A)
Immunoblot showing Tat protein levels in cellular extracts of HCN cells cultured in
proliferating (P) or differentiating (D) medium in the absence or presence of the calpain
inhibitor ALLN (10 μM). The cells were treated with 400 nM recTat101. (B) Densitometric
analysis of Tat in the samples treated with ALLN after normalization for Grb2 is shown
in the diagram and represents the average of at least three independent experiments.4. Stability of HIV-1 Tat in primary rat embryonic cortical neurons
In the next set of experiments, we have expanded our analysis to
differentiated primary rat embryonic neurons. Fig. 3 illustrates the
results from a typical experiment in which two-week old terminally
differentiated neuronal cultures were treated with recTat101 for
various time points in the absence or presence of the calpain 1
inhibitor ALLN (10 μM). Tat was detectable in cortical neurons 4 h after
treatment and the signal declined thereafter, being barely detectable
after 24 h. Instead, the inhibitory effect of ALLN onTat degradationwas
already evident after 4 h of Tat treatment and persisted for 24 h (Fig.
3A). Quantitatively, a two- and six-fold increase in Tat levels was
detected at 4 and 24 h, respectively, in the ALLN-pre-treated samples
(Fig. 3A, right panel). We also tested if other inhibitors such as
proteasomal inhibitors could stabilize intracellular Tat and prevent its
degradation. Cortical neurons were pre-treated with various calpain
and proteasome inhibitors before the addition of recTat101. The
results in Fig. 3B show that only the calpain inhibitor ALLN
signiﬁcantly prevented Tat degradation at the 24 h time point.
Quantitatively, a two-fold increase in Tat levels was detected in
samples pre-treated with ALLN, while no signiﬁcant effect on Tat
stability was observed for MG115 (1 μM), MG132 (1 μM) or Lactacystin
(1 μM) (Fig. 3B, right panel). Note that at micromolar concentrations,
MG115 and MG132 can also inhibit the proteolytic activity of calpain
[19]. In addition, we have evaluated the cleavage of αII-spectrin
(fodrin) as a control for calpain activity in differentiated neurons
[20,21]. Fig. 3B, middle panel, shows that in untreated neurons fodrin
was presentmostly in the cleaved forms (lane 1) and Tat treatment did
not affect fodrin levels (lane 2). Pre-treatment of neuronal cultures
with the calpain inhibitor ALLN prevented fodrin cleavage (lane 3),
further suggesting the presence of calpain activity in differentiated
neurons. Interestingly, treatment with MG115 or MG132 proteasomal
inhibitors enhanced fodrin stability but did not prevent its cleavage
(lanes 4 and 5) and the amount of cleaved fodrin (150/145 kDa) was
comparable to control untreated cells. Similar to the pattern observed
in untreated samples, treatment of neuronal cultures with the
proteasome irreversible inhibitor lactacystin did not have any effect
on fodrin (Fig. 3B, lane 6).
Since Tat has been shown to activate the NMDA receptor, we
compared the stability of intracellular Tat in cortical neurons
pretreated with the calpain inhibitor ALLN (10 μM) or with the
NMDA antagonist MK801 (10 μM) (Fig. 3C). No difference in Tat levels
was observed in the ﬁrst 4 h after addition of recTat101 in control (no
inhibitors), ALLN-, or MK801-treated cultures (lanes 2–4). When
compared to cells treated with Tat alone (lane 6), a slightly higher
amount of Tat was observed in the cellular lysates obtained from ALLN
or MK801-treated neuronal cultures at 24 h (lanes 7 and 8,
respectively). However, the difference between ALLN and MK801
treatments on Tat stability increased after 48 h when the apparent
inhibitory effect of MK801 on Tat degradation was completely lost
(lane 12). Quantitatively, a three-fold decrease in intracellular Tat
occurred in the ﬁrst 24 h. ALLN treatment prevented Tat degradation
and similar levels of the protein were sustained for up to 48 h, while
MK801 had a limited, if any, effect on Tat stability (Fig. 3C, right panel).
Of note, all the inhibitors (proteasome, calpain, and NMDA receptor)
showed cytotoxic effects after 48 h treatment.
We have shown that the synthetic calpain inhibitor ALLN
efﬁciently prevents Tat degradation in cell culture. We further
evaluated whether activity of calpain-mediated Tat cleavage was
affected by calpastatin, the endogenous inhibitor of calpain 1 [22,23].
We utilized a shorter acetyl-calpastatin peptide (50 μM) to inhibit the
activity of calpain 1 in primary rat neurons. Fig. 3D shows the levels of
recTat101 in protein extracts obtained from calpastatin-treated and
control untreated cortical neurons after 4 and 24 h. These results show
that treatment of primary neurons with calpastatin efﬁciently
prevented the cleavage of intracellular Tat101.
Fig. 3. Effects of calpain and proteasome inhibitors on Tat protein levels in rat primary cortical neurons. In all the experiments, Grb2 was used as the loading control and to normalize Tat
levels. Densitometric analyses ofWestern blots depicted in panels A–C are shown on the right side of each panel. Data represent average values from three independent experiments with
standard deviation. (A) Western blot analysis to detect Tat in cortical neurons treated with the calpain inhibitor ALLN (10 μM) at the indicated time points. In the graph, ⁎ and ⁎⁎ indicate
values statistically different from Tat 4 h and Tat 24 h, respectively (p≤0.05). (B) Comparison of the effects of various calpain and proteasome inhibitors (10 μM ALLN, 1 μMMG115, 1 μM
MG132,1 μMLactacystin) on the stability of Tat (upper panel). The same blotwasprobedwith anti-fodrin antibody to showcalpain activity. Note that only ALLN treatment prevented fodrin
cleavage,whileMG115andMG132, althoughenhanced250kDa fodrin stability, didnot prevent its cleavage. Lactacystin treatmenthadnoeffects onneuronal fodrin. In thegraph,⁎ indicates
values statistically different fromall other values represented (p≤0.05). (C)Westernblot showing that inhibitionofNMDA receptor byMK801 (10 μM)doesnot protect Tat fromdegradation.
In the graph, ⁎ and ⁎⁎ indicate values statistically different from the values related to the same time points inTat or Tat+MK801 (p≤0.05). (D)Western blot showing the effect of calpastatin
on the intracellular degradation of Tat. Rat embryonic cortical neurons were pre-treated with acetyl-calpastatin peptide for 1 h before the addition of recTat101 for 4 and 24 h.
381G. Passiatore et al. / Biochimica et Biophysica Acta 1793 (2009) 378–387
382 G. Passiatore et al. / Biochimica et Biophysica Acta 1793 (2009) 378–3875. In vitro cleavage of Tat by calpain 1
To examine the effect of calpain on Tat we performed an in vitro
assay of Tat cleavage using puriﬁed calpain 1. RecTat101 was used as a
substrate and incubatedwith calpain 1 in the presence of Ca2+ for 2 h as
shown in Fig. 4A. Western blot analysis using an antibody against the
N-terminus of Tat detected a band of about 14 kDa corresponding to
the uncleaved Tat on a 15% poly-acrylamide gel both at time 0 and after
2 h at 37 °C (lanes 1 and 9, respectively). A progressive decrease of this
band occurred after 15 min of incubation with calpain 1 (not shown)
and continued up to 2 h (lane 2). Cleavage of Tat was prevented by the
calpain 1 inhibitor ALLN (10 μM) (lane 3), and partially by the highest
concentration of the proteasome inhibitor MG132 (1 μM) (lane 6). It
has been reported that MG132 can inhibit both proteasome and
calpain activities when used at micromolar concentration. In line with
this dual effect of MG132, amounts of this inhibitor lower than 1 μM
could not prevent Tat-cleavage (lanes 4, 5 and 6). The calcium chelator
EDTA prevented cleavage of Tat (lane 8). A small band (below 7 kDa)
was recognized by an antibody to the N-terminus of Tat, only whenTat
was cleaved, suggesting that the calpain 1 sensitive site might map to
the C-terminus of Tat. To further investigate the calpain 1 sensitive
domain of Tat, we utilized GST-Tat fusion protein and conﬁrmed the
cleavage using an in vitro calpain assay. GST-Tat101 is about 38 kDa
(Fig. 4B, lanes 1 and 9). Addition of calpain 1 for various time points
to the reaction mix containing 2 mM CaCl2 generated a cleavage
product of about 34 kDa by 15 min. Similarly to the results obtained
with recTat101, the cleavage product of GST-Tat101 was not
detectable in the sample containing the calpain inhibitor ALLN
(lane 6) or the calcium-chelating agent EDTA (lane 8). By contrast,
the proteasomal inhibitor MG132 did not protect Tat from calpain-
mediated cleavage (lane 7). In a similar in vitro cleavage assay, we
could not detect any action of puriﬁed 20S proteasome on recTat101
(data not shown), supporting a proteasome-independent pathwayFig. 4. In vitro analysis of Tat cleavage by calpain 1. (A) Western blot showing Tat protein le
containing CaCl2. RecTat101 has an apparentmolecular weight of 14 kDa and is detectable at t
the presence of calpain 1 (lane 2), and ALLN or EDTA prevent the cleavage (lanes 3 and 8, resp
of 0.025, 0.25 and 1 μM, respectively. In lane 7 the effect of lactacystin (1 μM) are shown. In lan
staining to detect ∼38 kDa GST-Tat101 at the starting point (lane 1) and end point (2 h, lane 9
and 120 min, respectively. Cleavage is prevented by ALLN (lane 6) or EDTA (lane 8), but notfor Tat cleavage/degradation. Next, we investigated the domain/s of
Tat protein sensitive to the cleavage by calpain (Fig. 5). We utilized
GST-Tat fusion proteins, full-length and a series of Tat deletion
mutants. Deletion of 15 aa (GST-Tat86, Fig. 5A, lanes 3 and 4) at the
C-terminus of Tat did not protect the viral protein from cleavage.
Addition of calpain to the GST-Tat72 generated a shorter fragment
(Fig. 5A, compare lanes 5 and 6), while GST-Tat50 was uncleaved
under the same experimental conditions (Fig. 5B).
To determine the calpain 1 cleavage site within Tat, we again
performed the in vitro cleavage assay using recTat101. Uncleaved and
cleaved Tat peptides were subjected to electrospray mass spectro-
metry (ES-MS) followed by protein identiﬁcation analysis (as
described in Materials and Methods). Results in Fig. 5C show that
the Tat-fragment with the highest degree of conﬁdence (about 99%)
in protein identiﬁcation is a 3.176 kDa product, which has an amino
acid composition corresponding to the C-terminus of HIV-1 Tat101:
69LPKQPAPQFRGDPTGPKESKKKVERETETHPVD101. Therefore, the
putative cleavage site mapped between amino acids Ser68 and
Leu69 (Fig. 5D).
6. Toxicity of Tat101 is attenuated by the calpain inhibitor ALLN
Next, we have determined the toxicity of Tat101 in neuronal
progenitors, which are kept in proliferating medium or in differentiat-
ing conditions. Survival of neuronal progenitors at the times indicated
is represented in Fig. 6 as percentage increase or decrease of cell
number over 4 h. Expression of Tat101 is highly toxic to proliferating
cells and more than 30% of cells are lost in the ﬁrst 24 h post-
transfection, and an additional 30% is lost by 72 h. The impact of
Tat101 expression in differentiating neuronal cells is less dramatic and
cells survive for up to 24 h post-transfection; about 40% of cells are
then lost by 72 h, suggesting that induction of neuronal differentiation
might have a protective effect on Tat expressing cells thereby delayingvels after 2 h incubation of recombinant Tat101 with calpain 1 in the reaction mixture
ime 0 (lane 1), and after 2 h at 30 °C in the absence of calpain 1 (lane 9). Tat is degraded in
ectively). In lanes 4, 5 and 6 the reactionmixture containedMG132 at the concentrations
es 2, 4–7 the band below 7 kDa represents the Tat cleavage fragment. (B) Coomassie blue
). Lanes 2 to 5 show a cleavage product of Tat in the presence of calpain 1 for 15, 30, 60,
by MG132 (lane 7).
Fig. 5. Analysis of the sites of Tat sensitive to cleavage by calpain. (A) Coomassie blue staining of a 16.5% Tricine gel to detect Tat after in vitro calpain 1 cleavage assay of GST-Tat 101
and two C-terminus deletion mutants, Tat-86 and Tat-72. The asterisk below the arrow indicates the cleavage product of Tat72. (B) Similar experiment to show that GST-Tat50 and
GST alone are not cleaved by calpain. (C) Table showing electrospray mass spec results after analysis using Analyst QS software. % cov: % coverage of protein sequence; Prec: precise;
Theor: theoretical; m/z: mass/charge ratio; contrib: contribution; conf: protein conﬁdence of identiﬁcation; dMass: difference in mass between actual (prec) and theoretical values;
Sc: score. (D) Schematic diagram showing the site of Tat sensitive to calpain 1 cleavage (arrow).
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proliferating conditions increases over the time reaching more than
46% at 72 h, while induction of neuronal differentiation inhibits theFig. 6. Enhanced toxicity of Tat101 in proliferating than differentiating neuronal
progenitors. Toxicity was evaluated as percent increase or decrease of cell number at the
indicated times over the 4 h time point. Experiment was repeated three times, each
time in triplicate.growth without affecting the cell survival and the 30% increase of cell
number observed at 24 h remains at comparable levels over the
indicated time points.
With a similar approach, we have determined toxicity of the
putative Tat-cleavage products compared to the full-length protein
Tat101. We have generated two mutants of Tat101, the C-terminus
truncated Tat1–68 and the N-terminal deleted mutant Tat69–101.
For easy detection, the Tat sequences were cloned in frame with
enhanced YFP, and expression of the various Tat proteins was
evaluated by Western blot analysis using an antibody against YFP
(data not shown). The toxicity of the three Tat proteins (101, [1–] 68,
and 69–101) was evaluated in proliferating and differentiating
neuronal progenitors in the absence or presence of ALLN (10 μM)
at 4 and 24 h following nucleofection (Fig. 7A). The results are
presented as fold change of the number of green-positive cells
(control or Tat-constructs) treated with the calpain inhibitor ALLN
divided by the number of ALLN-untreated cells. YFP-positive cells
grew in proliferating conditions and the presence of ALLN did not
affect signiﬁcantly their growth over a 24 h period of time.
However, the effect of the calpain inhibitor was noticeable in
Tat101-expressing cells in which more than 2-fold increase in
survival was observed when cells were exposed to ALLN. As
expected, the protective effect of ALLN treatment was barely noticed
in Tat1–68-expressing neuronal progenitors and undetectable in
Tat69–101-transfected cells. Of interest, no signiﬁcant change in cell
number was observed when cells were grown in differentiating
Fig. 7. Role of calpain 1 in Tat-induced cell death. Neuronal progenitors were nucleofected with control, Tat101, Tat1–68 and Tat 69–101 plasmids as described in Materials and
methods. (A) Diagram showing fold-change of the number of green-positive ALLN-treated cells at 4 and 24 h over the untreated cells at the same time points and grown in
proliferating or differentiating medium. (B) Representative pictures of neuronal progenitors cells maintained in proliferating medium in the absence or presence of ALLN 24 h post-
nucleofection with Tat101 and the two truncated mutants Tat1–68 and Tat69–101.
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behaved essentially the same. Of note, exposure of neuronal
progenitors to ALLN during their differentiation inhibited neurite
outgrowth and a toxic effect was observed in our cell cultures 48 h
after treatment. Fig. 7B shows representative pictures of neuronal
progenitors 24 h after transfection with Tat101, Tat1–68, and Tat69–
101 plasmids cultured in proliferating medium in the absence or
presence of ALLN (left and right panels, respectively). The number of
green cells in Tat101-transfected progenitors was about 2-fold
higher in ALLN-treated compared to untreated cell cultures (upper
panels). As expected, the calpain inhibitor did not signiﬁcantly
change the number of both Tat1–68 (middle panels) and Tat69–101
(lower panels) positive cells.7. Differential afﬁnity of Tat86 and Tat101 for the nucleus
We have repeatedly observed a differential afﬁnity of Tat86 and
Tat101 for the nuclear compartment in differentiated cells (unpub-
lished observation). This differencemay account for delayed toxicity of
Tat101 in mature neurons and could be critical for the biological
activity of Tat in vivo. We have utilized Tat86 and Tat101 recombinant
proteins conjugated with FITC ﬂuorescent dye at a concentration of
2 μg/ml, and treated HCN cells (Fig. 8A) or primary cortical neurons
(Fig. 8B) for 24 h. Cells were ﬁxed and immuno-labeled with anti β3-
tubulin (Fig. 8A), or anti-SNAP25 synaptic protein (Fig. 8B). The
distribution pattern of FITC-Tat86 (green) in differentiating HCN
neuronal progenitors showed large clusters of the recombinant
Fig. 8. Subcellular localization of Tat86 and Tat101 in neuronal cells. Representative
pictures of neuronal cells after treatment with FITC-Tat86 and FITC-Tat101 for 24 h
followed by immunocytochemistry. (A) HCN neuronal progenitors undergoing neuronal
differentiationwere immunolabeled with anti-β3-tubulin. Original magniﬁcation 100×.
(B) Rat embryonic cortical neurons immunolabeled with anti-SNAP25 to emphasize
neuronal processes. Original magniﬁcation 40×. Pictures were deconvolved using the
SlideBook 4 imaging software.
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little β3-tubulin (red) colocalization (yellow) (Fig. 8A, upper panel).
On the other hand, FITC-Tat101 showed enhanced colocalization with
cytoplasmic β3-tubulin and more disperse nuclear clusters (Fig. 8A,
lower panel). Note that FITC-Tat101 was present in the growing
neuronal processes, where it also colocalized with β3-tubulin.
Dendritic localization of FITC-Tat101 but not FITC-Tat86 was more
evident in mature cortical neurons (Fig. 8B). FITC-Tat86 was not
detectable in the neuronal processes (Fig. 8B, upper panel), while
some dendritic localization of FITC-Tat101 followed the distribution
pattern of the synaptic protein SNAP25 (Fig. 8B, lower panel). Similar
results were obtained by transfecting neurons with plasmids encoding
the fusion proteins YFP-Tat86 and YFP-Tat101 (data not shown), whichindicates that the length of Tat may be determinant for its subcellular
distribution and function. Intracellular cleavage of Tat101 by calpain
may function as a switch changing the preference of Tat for the
cytoplasmic compartment toward the nuclear localization, possibly
contributing to the toxic activity of this viral protein.
8. Discussion
The HIV-1 regulatory protein Tat has been shown to be toxic to
neuronal cells and it has been implicated in the pathogenesis of
neuroAIDS [24,25]. Although the most abundant form of Tat in
primary isolates consists of at least 101 amino acids, truncated forms
of 72 and 86 amino acids are used in most studies, including our
previous work [16]. Because the ﬁrst exon of Tat (ﬁrst 72 amino
acids) contains the minimal sequence required for viral replication
[1,3], this region has received more attention than the C-terminal
second exon of Tat. Nevertheless, considering that cellular uptake
and activity of Tat might be also depend on its tertiary structure [26],
addition of another 29 amino acids to the Tat72 form may enhance,
attenuate, or somehow change the activity of this protein in cells,
particularly bystander cells, which are not infected by HIV-1, e.g.
neurons, which take up Tat from the brain milieu. Campbell et al.
reported that the last 14 residues in the C-terminus of Tat100 are
implicated in both a greater trans-activation ability and a reduced
ability to upregulate CD178 expression and induce apoptosis in T
cells [6].
In this study, we investigated the stability of HIV-Tat in neuronal
cells and found that neuronal progenitors undergoing neuronal
differentiation and fully differentiated cortical neurons retained Tat
for longer times than proliferating neuronal progenitors (Fig. 1).
However, independently from the differentiation status of the
neuronal cells, Tat degradation was prevented by the calpain 1
inhibitor ALLN in both neuronal progenitors and fully differentiated
primary neurons (Figs. 2 and 3). As an additional control the calpain-
mediated cleavage of Tat was further conﬁrmed by pre-treating
neuronal cultures with the endogenous inhibitor calpastatin before
addition of recombinant Tat. Our results show inhibition of Tat
degradation in primary neurons by the calpastatin-derived peptide
(Fig. 3D). Moreover, inhibition of calpain by ALLN prevented calpain 1-
mediated in vitro cleavage of both recTat101 and GST-Tat101 (Figs. 4
and 5). There is little information about secondary modiﬁcations of
HIV-1 Tat, especially the full-length Tat101. It has been shown that
Tat72 is cleaved by HIV proteases in vitro [13], and Tat86 is cleaved by
furin endopeptidase in monocytoid cells [14]. Tat cleavage mediated
by furin mapped within the basic domain of the viral protein, amino
acids 53–57, and generated a truncated protein with a reduced ability
to transactivate viral gene expression [14]. Of interest, although furin
is required for the processing of envelope glycoproteins from many
viruses including HIV-1 gp160 [27,28], low levels of expression have
been detected in neurons and glial cells of murine and human brain
[29,30], suggesting a limited, if any, role in the processing of Tat by
furin in neurons. Tat72 has been shown to be a substrate for matrix-
metalloprotease-1 (MMP-1) in neuronal–glial mix cultures. According
to this study, cleavage of Tat by MMP-1 may reduce neurotoxicity of
the viral protein by lowering its levels [17]. Using electrospray
ionization mass spectrometry of uncleaved versus cleaved recTat101
we have identiﬁed a cleavage product of a predicted molecular weight
of about 3.2 kDa corresponding to the amino acid sequence of Tat 69–
101 (Fig. 5). We have further investigated toxicity of Tat101 and its
calpain-derived peptides Tat1–68 and Tat69–101 in neuronal pro-
genitors maintained in proliferative status or in differentiating
conditions. When expressed endogenously, Tat101 is toxic to neuronal
progenitors maintained in proliferating medium and ALLN treatment
enhances cell survival, suggesting that cleavage by calpain 1 may
augment toxicity of Tat. In differentiating cells, however, expression of
Tat101 is less toxic and addition of ALLN has only a marginal effect on
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to Tat-mediated cell death.
Although many proteins have been identiﬁed as calpains sub-
strates, the mechanisms underlying substrate recognition remain to
be determined. Nonetheless, the amino acid sequence on Tat that we
have identiﬁed by mass spectrometry as cleavage site by calpain (His-
Asp-Val-Ser68-Leu-Pro-Lys in the recTAt101, or His-Asp-Val-Ser68-
Leu-Ser-Lys in the GST-Tat101) correlates with the study of Tompa et
al. showing that the preferred amino acid in position P2 (aa 2 before
the cleavage site) is valine and two of the preferred in P2′ (aa 2 after
the cleavage site) are serine or proline [31]. Interestingly, the amino
acid sequence Ser-Leu-Ser70 is well conserved among brain-derived
Tat isolates from AIDS patients with dementia (HIVD) [32]. About 50%
of the brain-derived Tat isolates have an aspartate residue in position
P2 instead of valine, which has a low score according to the matrix
proposed by Tompa et al., but is present in some known calpain
substrates, including Tau [31].
The importance of the C-terminal sequence of Tat in the cellular
uptake, and subcellular localization was investigated using FITC-
conjugated Tat86 and Tat101 recombinant proteins. As observed by
Ma et al. using 125I-labeled Tat72 and Tat86, we also observed
different behavior of Tat86 and Tat101. FITC-Tat86 showed a more
diffuse distribution pattern in the neuronal cytoplasm than FITC-
Tat101, while in the nucleus, the Tat86 formed larger clusters than
Tat101 (Fig. 8).
In summary, our observations and previous work prompt us to
investigate the intracellular processing of Tat in neuronal cells. The use
of calpain and proteasome inhibitors suggested a possible cleavage of
Tat by calpainwithout involvement of the proteasome, which is in line
with the recent study of Gargano et al. showing that p14(ARF)
promotes Tat degradation via a proteasome-independent pathway
and consequent inhibition of LTR transactivation [33]. The calpain 1
cleavage site mapped at position Ser68–Leu69 of Tat101, releasing an
amino-terminal peptide of 68 amino acids, and a shorter 32 amino
acid carboxy-terminal peptide, for which the only known functional
sequence identiﬁed is the RGD motif (integrin binding domain) [34].
Cleavage by calpain may enhance the afﬁnity of Tat for the nuclear
localization, therefore increasing its toxicity in neurons. Indeed, in
several instances nuclear localization is accompanied by increased
toxicity/cell death. This hypothesis is however challenged by the
observation that in human HIV-Encephalopathy (HIVE) brain tissues
immunodetection of Tat showed a prevalent cytoplasmic localization
in neurons. Perhaps the afﬁnity of Tat for the cytoskeletal components
[16] may mask or limit the access to the calpain cleavage site delaying
its nuclear translocation/toxicity. This might explain why mature
neurons survive better than proliferating neuronal progenitors to the
toxic effects of Tat, although further studies are needed to investigate
this possibility.
9. Materials and methods
9.1. Cell lines
Rat adult neuronal progenitors HCN-A94-2 (HCN) were a kind gift
of Dr. Fred Gage (The Salk Institute, La Jolla, CA) and are described
elsewhere [35]. HCN cells were grown on poly-ornitine/laminin
coated dishes in DMEM/F12 (1:1) medium containing N2 supple-
ment (Invitrogen, Carlsbad, CA), and 20 ng/ml basic FGF (bFGF, FGF2,
Sigma, St Louis, MO). Differentiating medium contained DMEM/F12
(1:1), N2 supplement, 1 μM retinoic acid and 0.1% FBS as previously
described [36].
To generate pEYFP-Tat1–68 and pEYFP-Tat69–101 fusion proteins the
PCR primers were: Tat1–68 forward: ACAAGCTTACATGGAGCCAGTA-
GATCCTAGC, and reverse: ACGGATCCTCAAGAAACTTGATGAGTCT-
GACTGC; Tat69–101 forward: ACAAGCTTACCTATCAAAGCAACCCACCTCC,
and reverse: ACGGATCCTC AAGCGCTCGGATCTGTCTCTG.9.2. Nucleofection of HCN cultures
For nucleofection, HCN cells (5–10×106/reaction) were centri-
fuged at 800 rpm for 5 min and resuspended in 100 μl of the
nucleofection solution (rat neuronal progenitors nucleofector kit,
Amaxa Inc. Gaithersburg, MD). The cell suspension was then mixed
with 5 μg of the appropriate plasmid, nucleofected using the
program A-33 and immediately plated in culture medium. When
required, the calpain inhibitor (ALLN, 10 μM) was added to the cell
cultures immediately after nucleofection. For cytoﬂuorescence
experiments, cells were plated on poly-ornitine/laminin coated
chamber slides.
To assess toxicity of Tat full-length and its truncated mutants, HCN
cells were nucleofected with YFP-Tat101, YFP-Tat1–68, YFP-Tat69–101
or YFP control vector as previously described and cultured on poly-
ornitine/laminin coated chamber slides in proliferating or differentiat-
ing conditions, and in the absence or presence of ALLN (10 μM).
Control and Tat-expressing cells were counted under a ﬂuorescent
microscope at 4, 24 and 48 h post-nucleofection. In Fig. 6 cell survival
was expressed as percent increase or decrease of green-positive cells
at the indicated time points over the 4 h time point. The experiment
was repeated in triplicate at least three times. In Fig. 7 cell survival is
expressed as fold change of green-positive ALLN-treated cells over the
untreated cultures at the same time point.
9.3. Recombinant proteins and inhibitors
Recombinant proteins Tat101 MN, FITC-Tat86 IIB and FITC-Tat101
MN were purchased from Immuno Diagnostics Inc. (Woburn, MA),
and used at the concentrations of 150 nM and 400 nM (about 2 and
5 μg/ml, respectively). The proteasome and calpain inhibitors MG115
(1 μM), lactacystin (1 μM), MG132 (1 μM), and ALLN (10 μM) were
from Calbiochem (EMD Chemicals, Inc. San Diego, CA). MK801
(10 μM) was also from Calbiochem. All the inhibitors used in this
study, including MK801, were tested for their toxicity in our cellular
models and used at the highest concentration at which no toxic effect
was observed for up to 48 h. Acetyl-Calpastatin inhibitor fragment
184–210 was from Sigma (Sigma, St Louis, MO). When required,
calpastatin (50 μM) was added to the cellular cultures 1 h prior to Tat
treatment.
9.4. Western blots
Cells, primary rat cortical neurons and HCN-A94-2, were collected
by scraping the plates in the presence of PBS, followed by
centrifugation and lysis of the cell pellet in the appropriate volume
of RIPA buffer (50 mM Tris pH 7.4, 1% NP-40, 0.25% sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF,
1 mM sodium orthovanadate, phosphatase inhibitors and protease
inhibitor cocktails). Fifteen to ﬁfty micrograms of whole cell lys-
ate were separated on a 4–15% SDS-PAGE (BioRad, Hercules, CA).
The antibody against Tat was the monoclonal antibody from
ImmunoDiagnostics Inc. (Woburn, MA). Anti-Grb2 was from Trans-
duction Laboratories (BD Biosciences, San Jose, CA). Anti-fodrin
(spectrin) antibody was from Chemicon (Chemicon International
Inc., Billerica, MA)
9.5. Fluorescence microscopy
For cytoﬂuorescence analysis primary rat neurons were grown in 2
or 8 chamber slides (BD Falcon, BD Biosciences Discovery Labware,
Bedford, MA) coated with an aqueous solution containing poly-D-
lysine and laminin (1:1) at concentrations of 0.01 and 0.005 mg/ml,
respectively. HCN cells were grown on poly-ornithine/laminin coated
glass chamber slides. When required, FITC-Tat86 and FITC-Tat101
recombinant proteins were added to the culture medium. Cells were
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free) ultrapure EM grade (Polysciences Inc, Warrington, PA) for 20min
at 4 °C. After two washes with phosphate-buffered saline (PBS), the
slides were mounted with Vectashield mounting medium containing
4′6′-diamidino-2-phenylindole (DAPI; Vector Laboratories Inc, Bur-
lingame, CA). Anti-β3-tubulin was from Chemicon (Chemicon Inter-
national Inc., Billerica, MA) and anti-SNAP25 was from Abcam (Abcam
Inc., Cambridge, MA).
9.6. Deconvolution analysis
Deconvolution of selected pictures was performed using the
SlideBook 4 imaging software (Intelligent Imaging Innovations,
Denver Co.). In brief, a series of three-dimensional images of each
individual picture were deconvoluted to one two-dimensional picture
and resolved by adjusting the signal cut-off to near maximal intensity
to increase resolution.
9.7. Overexpression and puriﬁcation of GST-recombinant Tat
GST, GST-Tat101 [37] and Tat deletion mutant fusion proteins were
prokaryotically expressed and puriﬁed as described previously [38].
The integrity and purity of the GST fusion proteins were analyzed by
SDS-PAGE followed by Coomassie blue staining. Known amounts of
BSA were included as controls on the same gel.
9.8. Calpain 1 assay
For in vitro calpain cleavage assay, calpain-1 was purchased from
Calbiochem (EMD Chemicals, Inc., San Diego, CA). In vitro calpain
cleavage was performed as previously described [39]. Brieﬂy, 1 μg of
GST-Tat or 250 ng of recombinant Tat101 protein were reacted with
200 nM or 600 nM of Calpain-1, respectively. The reactionwas carried
out in a buffer containing 20mMTris–HCl, pH 7.4, 2mMCaCl2 at 30 °C.
Reactions were terminated by addition of SDS sample buffer. GST-Tat
was analyzed by electrophoresis on 4–15% poly-acrylamide gels
(BioRad) and Coomassie blue staining. Recombinant Tat101 protein
was analyzed by electrophoresis on a 15% Tris–Glycine SDS-PAGE
(BioRad, Hercules, CA), followed by Western blot.
9.9. Mass spectrometry
Equipment and software were available in the Proteomics Core
Facility at the University of Pennsylvania. 250 ng of recTat101 were
incubated in a reaction buffer in the absence or presence of calpain 1
and analyzed with a nanospray/Qstar-XL mass spectrometer (Applied
Biosystems, Foster City, CA). For microsequencing, peptide samples
were dissolved in 5 μl of 0.1% formic acid, injected into a C18 capillary
column, and eluted by linearly increasing the mobile phase composi-
tion to 98% B (0.1% formic acid in 100% acetonitrile) at a ﬂow rate of
200 nl/min. The data were acquired and analyzed with Analyst QS
[40]. The protein identiﬁcation and database search were performed
with Mascot dll script of Analyst QS; the combined MS and MS/MS
data were used for the Mascot database search. A protein score of N70
with a protein conﬁdence of identiﬁcation of N95% was considered
acceptable [41].
9.10. Statistical analysis
All results are represented as mean values±SD. The signiﬁcance of
differencesbetweenmeanswasperformedusing a two-tailed Student's
t test. p values ≤0.05 were considered to be statistically signiﬁcant.Acknowledgements
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